Willow Laboratories has been acquired by Boston-based private equity firm Ampersand Capital Partners.
Willow is a clinical and forensic toxicology laboratory providing urine, hair and saliva testing services to a wide range of healthcare providers including treatment centres, physician practices, and other laboratories.
Using state-of-the-art technology, Willow provides qualitative and quantitative alcohol and drugs-of-abuse test results to aid clients in the diagnosis and treatment of substance abuse.
Gail Marcus has joined Willow as president and chief executive officer. Marcus has significant experience building healthcare service organisations and was recently chief executive of Caris Diagnostics (now Miraca Life Sciences), a national diagnostic pathology laboratory.
Marcus also serves as president and chief executive of Calloway Laboratories, which recently signed a definitive agreement to be acquired by Ampersand.
"I am excited to be working with the Willow and Calloway management teams and look forward to sharing strengths and resources across the companies in order to provide clients the most-complete set of toxicology lab services available in the marketplace," says Marcus.
Jared Bartok, general partner at Ampersand, says: "Willow is another key piece of our strategy to invest in the multi-billion dollar toxicology lab industry. With the infusion of additional capital and management resources, Willow is well positioned to capitalise on future growth opportunities in the substance abuse market while implementing a zero tolerance compliance policy."
